Assistant Professor; Director of Research - Immunovaccine, Inc.
Phone: 902-421-5735 ext 5
1344 Summer Street
Halifax Nova Scotia Canada B3H 0A8
- Cancer Immunotherapy
- Vaccine Development
- Infectious Disease
BSc, Biology, Memorial University of Newfoundland
MSc, Medicine, Memorial University of Newfoundland
PhD, Microbiology and Immunology, Dalhousie University
Postdoctoral Training, Robarts Research Institute, London, Ontario and Ottawa Hospital Research Institute, Ottawa, Ontario
The research interests of Immunovaccine include the development of a patented DepoVaxTM vaccine adjuvanting platform and vaccines - candidates for use in cancer immunotherapy, infectious disease and animal health.
- Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, Macdonald LD, Weir GM, Stanford M.M., Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 2012. Aug 3;10:156
- Evgin, L., Vaha-Koskela M., Rintoul, J., LeBoeuf F., Falls, T., Barrett J.W., Bell, J.C. and Stanford, M.M. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Molecular Therapy 2010. May;18(5):896-902.
- Stanford M.M., Shaban M., Barrett J.W., Werden S.J., Gilbert P., Bondy-Denomy J., MacKenzie L., Graham K.C, Chambers A.F and McFadden G. Myxoma virus oncolysis of primary and metastatic mouse tumours in vivo. Molecular Therapy. 2008 Jan; 16(1): 52-59.
- Stanford, M.M., Barrett, J.W, Nazarian S.H, Werden, S., and McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. Journal of Virology (2007) 81(3): 1251-60
Selected awards and honours
- Faculty of Medicine Postdoctoral Award of Excellence, University of Ottawa, 2008